首页> 外文期刊>The Lancet >Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial
【24h】

Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial

机译:接受经皮冠状动脉介入治疗(SORT OUT VI)的未选患者中使用Zotarolimus洗脱的耐久聚合物涂层支架与使用Biolimus洗脱的可生物降解聚合物涂层支架:一项随机,非劣效性试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background New-generation drug-eluting coronary stents have reduced the risk of coronary events, especially in patients with complex disease or lesions. To what extent different stent platforms, polymers, and antiproliferative drugs affect outcomes, however, is unclear. We investigated the safety and efficacy of a third-generation stent by comparing a highly biocompatible durable-polymer-coated zotarolimus-eluting stent with a biodegradable-polymer-coated biolimus-eluting stent.
机译:背景技术新一代的药物洗脱冠状动脉支架降低了冠状动脉事件的风险,特别是在患有复杂疾病或病变的患者中。但是,目前尚不清楚不同的支架平台,聚合物和抗增殖药物在多大程度上影响预后。我们通过比较高度生物相容性的耐用聚合物涂层的zotarolimus洗脱支架与可生物降解的聚合物涂层的biolimus洗脱支架,研究了第三代支架的安全性和有效性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号